引用本文: | 任长友1,杨水新2*,方红梅3.药物性皮肤损害与HLA-B相关性研究进展[J].中国现代应用药学,2009,(5):368-371. |
| REN Changyou1, YANG Shuixin2*, FANG Hongmei3.Advance of HLA-B Alleles and Sever Cutaneous Advers Drug Reactions[J].Chin J Mod Appl Pharm(中国现代应用药学),2009,(5):368-371. |
|
|
摘要: |
近期文献研究表明,人类白细胞抗原B等位基因多态性与一些药物的严重皮肤损害有关。本文重点介绍了HLA-B*1502与卡马西平, HLA-B*5801与别嘌呤醇,HLA-B*5701与阿卡巴韦所致严重皮肤损害的相关性研究进展,HLA-B具种族特异性和区域限制性,HLA-B*1502可作为特异性生物标志物用于东南亚裔人群卡马西平不良反应的预防性检测。 |
关键词: 人类白细胞抗原,基因多态性,严重皮肤反应 |
DOI: |
分类号: |
基金项目: |
|
Advance of HLA-B Alleles and Sever Cutaneous Advers Drug Reactions |
REN Changyou1, YANG Shuixin2*, FANG Hongmei3
|
Abstract: |
Resent literatures have reported genetic associations between polymorphisms of human leukocyte antigen B(HLA-B) alleles and severe cutaneous adverse drug reactions(SCADR). The review addressed the advance of relationship between HLA-B*1502 with carbamazepine, HLA-B*5801 with allopurinol, HLA-B*5701 with abacavir. The genetic association of HLA-B and SCADR is ethnicity specific and district restriction. HLA-B*1502 could be a valuable specific biomarker in preventing carbamazepine-induced SJS/TEN in south-east Asian countries. |
Key words: HLA-B gene polymorphisms serve cutaneous adverse drug reactions |